The infusion is a routine medical act. The marketing is where clinics get into trouble — reversing aging, repairing DNA, treating addiction. Here is the defensible version.
NAD+ Infusions: What You Can and Cannot Claim Read More »
Titrating per label is not microdosing. Deliberately staying sub-therapeutic and advertising it for longevity or metabolic health is a different question entirely.
GLP-1 Microdosing: A Trend Without an Approved Basis Read More »
Retatrutide is investigational, not approved for any indication, and has no lawful compounding pathway under 503A or 503B. What is actually in the vials being sold.
Retatrutide: Why There Is No Legal Way to Prescribe or Compound It Read More »
The shortages that made compounded semaglutide and tirzepatide possible are over, the grace periods expired, and FDA has moved to close the remaining route.
Compounded GLP-1s After the Shortage Ended: What Actually Changed Read More »
